相似文献
1
Targeted therapies in epithelial ovarian cancer.
J Oncol. 2010;2010:314326. doi: 10.1155/2010/314326. Epub 2010 Jan 13.
2
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6.
3
Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Enzymes. 2018;44:83-101. doi: 10.1016/bs.enz.2018.08.004. Epub 2018 Oct 5.
4
Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
Expert Rev Anticancer Ther. 2014 Sep;14(9):1041-50. doi: 10.1586/14737140.2014.922415. Epub 2014 Jun 23.
5
Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments.
Ecancermedicalscience. 2016 Mar 8;10:626. doi: 10.3332/ecancer.2016.626. eCollection 2016.
6
Targeted therapies for treatment of recurrent ovarian cancer.
Clin Adv Hematol Oncol. 2014 Mar;12(3):158-62.
7
MMPs in ovarian cancer as therapeutic targets.
Anticancer Agents Med Chem. 2012 Sep;12(7):764-72. doi: 10.2174/187152012802650174.
8
[The molecular biology of epithelial ovarian cancer].
Bull Cancer. 2012 Dec;99(12):1161-73. doi: 10.1684/bdc.2012.1667.
9
Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
Oncol Rep. 2012 Aug;28(2):395-408. doi: 10.3892/or.2012.1833. Epub 2012 May 25.
10
Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials.
Crit Rev Oncol Hematol. 2016 Feb;98:180-8. doi: 10.1016/j.critrevonc.2015.10.006. Epub 2015 Nov 10.
引用本文的文献
1
Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review.
Onco Targets Ther. 2021 Dec 1;14:5363-5372. doi: 10.2147/OTT.S335139. eCollection 2021.
2
Gentisyl Alcohol Inhibits Proliferation and Induces Apoptosis via Mitochondrial Dysfunction and Regulation of MAPK and PI3K/AKT Pathways in Epithelial Ovarian Cancer Cells.
Mar Drugs. 2019 Jun 3;17(6):331. doi: 10.3390/md17060331.
3
Hormone-receptor expression status of epithelial ovarian cancer in Ibadan, South-western Nigeria.
Pan Afr Med J. 2017 Aug 8;27:259. doi: 10.11604/pamj.2017.27.259.11883. eCollection 2017.
4
Pattern of triple negative epithelial ovarian cancer in indigenous African women.
F1000Res. 2016 Sep 28;5:2415. doi: 10.12688/f1000research.9632.1. eCollection 2016.
5
High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.
Int J Gynecol Pathol. 2014 Jul;33(4):402-10. doi: 10.1097/PGP.0000000000000081.
6
Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
BMC Cancer. 2013 Nov 16;13:549. doi: 10.1186/1471-2407-13-549.
7
Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profile.
Int J Clin Exp Med. 2013 Aug 1;6(7):552-61. Print 2013.
8
Ovarian cancer and DNA repair: DNA ligase IV as a potential key.
World J Clin Oncol. 2013 Feb 10;4(1):14-24. doi: 10.5306/wjco.v4.i1.14.
9
Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model.
PLoS One. 2012;7(8):e43577. doi: 10.1371/journal.pone.0043577. Epub 2012 Aug 27.
10
Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling glucose regulatory protein 78 and AMPK.
Oncotarget. 2012 Apr;3(4):435-49. doi: 10.18632/oncotarget.483.
本文引用的文献
1
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.
2
Novel agents on the horizon for cancer therapy.
CA Cancer J Clin. 2009 Mar-Apr;59(2):111-37. doi: 10.3322/caac.20003.
3
Beyond chemotherapy: targeted therapies in ovarian cancer.
Nat Rev Cancer. 2009 Mar;9(3):167-81. doi: 10.1038/nrc2583.
4
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.
Gynecol Oncol. 2009 Apr;113(1):21-7. doi: 10.1016/j.ygyno.2008.12.003. Epub 2009 Jan 21.
5
Epidemiology of ovarian cancer.
Methods Mol Biol. 2009;472:413-37. doi: 10.1007/978-1-60327-492-0_20.
6
Targeted therapy for cancer using PARP inhibitors.
Curr Opin Pharmacol. 2008 Aug;8(4):363-9. doi: 10.1016/j.coph.2008.06.016.
7
Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
J Clin Oncol. 2008 Jul 1;26(19):3259-67. doi: 10.1200/JCO.2007.11.3902.
8
A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
J Clin Oncol. 2008 Aug 1;26(22):3785-90. doi: 10.1200/JCO.2008.16.0812. Epub 2008 Jun 30.
9
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
Gynecol Oncol. 2008 Aug;110(2):140-5. doi: 10.1016/j.ygyno.2008.04.018. Epub 2008 Jun 13.
10
The promise and perils of 'targeted therapy' of advanced ovarian cancer.
Oncology. 2008;74(1-2):1-6. doi: 10.1159/000138349. Epub 2008 Jun 9.
Zotero 插件